Lv43
440 积分 2024-08-09 加入
SOHO State of the Art Updates and Next Questions | Update on Treatment-Free Remission in Chronic Myeloid Leukemia (CML)
1天前
已完结
Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study
7天前
已完结
Treatment Free Remission (TFR) in Chronic Phase‐Chronic Myeloid Leukemia (CP‐CML): Analysis of Predictive Factors and Novel Baseline Scoring System to Predict Molecular Relapse
7天前
已完结
How to improve treatment‐free remission eligibility in chronic myeloid leukaemia?
27天前
已完结
Development of a deep‐learning model tailored for HER2 detection in breast cancer to aid pathologists in interpreting HER2‐low cases
1个月前
已完结
Bispecific antibody based therapeutics: Strengths and challenges
1个月前
已完结
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
1个月前
已完结
The value of bispecific antibodies in relapsed and refractory DLBCL
1个月前
已完结
Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation
2个月前
已完结
U.S. Expert Consensus on Defining Intolerance to Tyrosine Kinase Inhibitor Treatment in Chronic Phase Chronic Myeloid Leukemia (CML)
2个月前
已关闭
皖公网安备34019202002308
